All posts by imreal

Lulu’s Law Introduced in Congress


It is very special to have Lulu’s name attached to this historic legislation that will improve sepsis care and help spare other families the shock and grief of losing a child.

Ana Lucía “Lulu” Haynes was a healthy child from Montclair, New Jersey, who was known to her family and friends for her sweet, spunky, and bright personality. She attended preschool and loved activities such as dancing and skiing. In 2014, Lulu passed away suddenly from sepsis after an appendectomy. She was just four years old.

Now, a bipartisan, bicameral bill focused on improving sepsis data collection has been introduced in Congress, and it’s named in Lulu’s honor. The National Sepsis Data Trust, Research, Outcomes, and Innovation Act (S.4827/H.R.8865), or “Lulu’s Law,” would authorize the establishment of a national sepsis data trust within the Department of Health and Human Services (HHS) and would enable states to launch sepsis data pilot programs to eventually feed into the trust. This would give healthcare professionals, researchers, innovators, public health officials, and others fighting sepsis on the frontlines access to critical information about sepsis – which could save many lives and limbs. The legislation is jointly sponsored by Congresswoman Mikie Sherrill (NJ-11), representing Lulu’s district, and Senators Bill Cassidy (R-LA) and Bob Casey (D-PA).

Sepsis, the body’s overwhelming and often life-threatening response to infection, constitutes a major public health concern in the United States. It affects 1.7 million people in the U.S. each year, taking the lives of over 350,000 adults and 6,800 children. It leaves many more survivors with amputations, post-sepsis syndrome, and other long-term effects.

For other widespread health problems, like cancer, data hubs or trusts allow for the reporting, tracking, and sharing of privacy-protected condition-related data at the national level. These informational hubs help experts understand how diseases and conditions affect the population, what progress has been made, and what therapies are still needed. Diagnosis, treatment, and innovation strategies can improve and adjust accordingly. But there is no such data hub for sepsis, so experts lack critical information about the condition that remains the leading cause of death in U.S. hospitals. Lulu’s Law would change this landscape.

“It is very special to have Lulu’s name attached to this historic legislation that will improve sepsis care and help spare other families the shock and grief of losing a child,” said Lukas Haynes, Lulu’s father and member of the Sepsis Alliance Board of Directors. “More than 1.7 million people in the U.S. are diagnosed with sepsis each year – one every 20 seconds – and the incidence is rising. Lulu’s Law will establish a national sepsis data trust to improve care and accelerate innovation to prevent, diagnose, and treat patients and support survivors. We are grateful to the bill’s bipartisan co-sponsors, their staff members, and everyone at Sepsis Alliance for their work on the bill. We look forward to celebrating its passage as soon as possible.”

“Clinicians, researchers, innovators, and others fighting sepsis on the front lines cannot manage what is not measured,” said Thomas Heymann, President and CEO of Sepsis Alliance, in the press release distributed by Representative Sherrill’s office. “Better sepsis data collection will allow us to answer some of the most fundamental questions about this deadly condition. Eventually, it will enable us to diagnose sepsis more quickly, predict who is most at risk, understand which treatments work best, target our use of antimicrobials, close inequitable care gaps, and innovate to deliver the best possible patient outcomes.”

To read the bill text, click here: S.4827 / H.R.8865

To learn more about sepsis, visit sepsis.org.

Share article on social media or email:

Privileged Chiral Spiro Ligands and Applications to Commercially Marketed APls


Raybow PharmaScience Logo

Raybow PharmaScience Logo

These privileged chiral spiro ligands can be applied to a number of chemical transformations including asymmetric hydrogenation, asymmetric carbonyl reductions, cross-coupling (C-C, C-N, C-B), hydroboration/diboration and nucleophilic addition reactions.

Raybow PharmaScience (Raybow) is pleased to highlight the use of privileged chiral spiro ligands for asymmetric synthesis with successful application to a number of commercially marketed APls. The key is more than 200 privileged chiral ligands with high enantioselectivity, high turnover number, high stability, ease of handling and readily tunable that Raybow has licensed from a number of leading academic researchers, specifically Professors Qilin Zhou (Nankai University) and Wenjun Tang (Shanghai Institute of Organic Chemistry).

It is important to note that these privileged chiral spiro ligands are free and clear of any Intellectual Property issues and their use will not require any royalty payments from Raybow’s clients.

These privileged chiral spiro ligands can be applied to a number of chemical transformations including asymmetric hydrogenation, asymmetric carbonyl reductions, cross-coupling (C-C, C-N, C-B), hydroboration/diboration and nucleophilic addition reactions.

Raybow has applied these privileged chiral ligands to a number of client projects, ranging from Process R&D to metric tonne manufacturing campaigns. Examples include Crizotinib (asymmetric reduction of a carbonyl intermediate; 1 00’s of Kg per annum), Ensartinib (asymmetric reduction of a carbonyl intermediate; MT per annum), Rivastigmine (asymmetric reduction of a carbonyl intermediate, 1 00’s of Kg per annum) and Aleglitazar (asymmetric hydrogenation; clinical supplies to Phase III). For all these examples more concise and/or higher yielding manufacturing processes with lower costs were developed.

Raybow has further demonstrated the viability of these privileged chiral spiro ligands by their application to a number of other commercially marketed APls at gram to kilo-gram scale. These APls include Montelukast (asymmetric reduction of a ketoester intermediate), Ezetimibe (asymmetric reduction of a ketoacid intermediate), Clopidogrel (asymmetric reduction of a ketoacid intermediate), Dapoxetine (asymmetric reduction of a beta-ketoester intermediate), Empagliflozin (asymmetric reduction of a lactone intermediate) and Silodosin (asymmetric hydrogenation of an olefin intermediate).

We have included 2 examples that showcase our work on our website. View them in our news room.

Raybow will be happy to discuss the potential applicability of these privileged chiral spiro ligands for your chemistry needs. For more information on our services you can visit our website. We showcase some of our R&D capabilities and expertise in Green Chemistry.

Meet us at CPhI Europe (November 1-3, 2022, Frankfurt, Germany) and BioEurope (Oct 24 – 26, 2022, Leipzig, Germany).

Share article on social media or email:

Ascent Protein Adds Pre-Workout Product to its Product Lineup at The Vitamin Shoppe


Ascent Pre-Workout Blueberry Raspberry flavor

Ascent’s Blueberry Raspberry Pre-Workout is an ideal addition to The Vitamin Shoppe’s product offerings

Ascent Protein, a sports nutrition company offering clean products for athletes and fitness enthusiasts, announced that The Vitamin Shoppe will now permanently stock its highly popular Blueberry Raspberry Pre-Workout product in 690 stores nationwide. Sourced from the highest quality clean ingredients, Ascent Pre-Workout promises to help provide clean energy and support athletic performance without any artificial flavors or sweeteners.

“Ascent’s Blueberry Raspberry Pre-Workout is an ideal addition to The Vitamin Shoppe’s product offerings,” said Dallas Doiron, Associate Director of Sales for Ascent. “We are thrilled to offer this new flavor as a permanent expansion to The Vitamin Shoppe’s shelves. The category today is oversaturated with high stimulant, synthetic, artificial drinks and Ascent’s version gives consumers a clean choice that they can trust, to get just the right energy and focus. The Vitamin Shoppe customers are dedicated to becoming their best self and we are dedicated to supplying them with the right products to get there.”

Ascent Pre-Workout has an unbeatable taste with no artificial flavors or sweeteners, supplying a clean source of energy and hydration to help fuel your workouts. One serving contains 150 mg of caffeine naturally sourced from coffee fruit extract and 250 mg of electrolytes to replenish hydration lost through exercise. In addition to Blueberry Raspberry, The Vitamin Shoppe customers can pick up two other Pre-Workout flavors: Orange Mango and Raspberry Lemonade.

Ascent product offerings in The Vitamin Shoppe include Native Fuel(R) Whey Protein Powder, and Organic Plant Protein powder blend.

Since launching in 2016, Ascent has quickly become one of America’s fastest growing sports nutrition companies. Consumers continue to praise Ascent’s products as one of the top-rated whey proteins on Amazon. Ascent Protein is trusted by some of the world’s most prominent elite athletes, including professional running back Jonathan Taylor, two-time CrossFit Games Champion Katrin Davidsdottir, and Team USA Weightlifting athletes CJ Cummings and Jourdan Delacruz.

###

About Ascent Protein

Ascent® was created to naturally improve athletic performance and is The Official Sponsor of Hard Work®. Ascent launched in 2016 and has continued to bring innovative products to the market, while remaining committed to their high-quality standards and offering products with straight-forward ingredients and nothing artificial. All Ascent products contain zero artificial flavors and sweeteners and are Certified Gluten Free, and Informed Choice Certified meaning they are third party tested for banned substances. Aligning with the admirable qualities in the athletes that Ascent serves – going the extra mile, completing an extra set, and never backing down from a challenge, Ascent pushes for high-quality results, knowing they do not come without hard work. For more information, visit http://www.ascentprotein.com.

About The Vitamin Shoppe®

Lifelong Wellness Starts Here™. The Vitamin Shoppe®, a subsidiary of Franchise Group Inc. (NASDAQ: FRG), is a global, omnichannel specialty retailer and wellness lifestyle Company with the mission of providing customers with the most trusted products, guidance, and services to support them on their journeys of lifelong wellness. Based in Secaucus, New Jersey, the Company offers a comprehensive assortment of nutritional solutions, including vitamins, minerals, specialty supplements, herbs, sports nutrition, homeopathic remedies, green living products, and natural beauty products. In addition to carrying products from approximately 700 national brands, The Vitamin Shoppe offers products from its proprietary brands within its owned and wholesale channels, including: The Vitamin Shoppe®, Vthrive null [The __title__ null] Vitamin Shoppe™, BodyTech®, BodyTech® Elite, fitfactor™, fitfactor KETO™, plnt®, ProBioCare®, True Athlete®, and TrueYou™. In the U.S., the Company conducts business through over 700 company-operated retail stores under The Vitamin Shoppe and Super Supplements™ banners, and via its website, http://www.vitaminshoppe.com. The company is expanding its retail footprint via an innovative, omnichannel franchising model and opened its first franchise store in 2022. Globally, The Vitamin Shoppe serves customers in select Asia, South America, and Central America markets through local omnichannel partners.

Share article on social media or email:

VA names NeuroFlow a finalist in $20 million Mission Daybreak grand challenge to reduce Veteran suicides


The U.S. Department of Veterans Affairs has named NeuroFlow as a finalist in Mission Daybreak — a $20 million challenge designed to help VA develop new suicide prevention strategies for Veterans. As a finalist, NeuroFlow will receive $250,000 and advance to Phase 2 of the challenge.

Co-founded by a U.S. Army Veteran, NeuroFlow supports organizations in their efforts to improve behavioral health access and support for Veterans. Partners, including The Wounded Warrior Project, Stop Soldier Suicide, BraveHearts, can utilize the company’s technology to provide Veterans with 24/7 access to confidential, personalized resources to support their overall wellness. “Properly supporting the behavioral health of our Veterans requires innovative, technology-driven solutions,” notes Army Veteran and NeuroFlow’s VP of Clinical Operations Matt Miclette. “The efforts of Mission Daybreak align directly with the DNA and mission of NeuroFlow; we’re honored to be a part of this challenge and join a diverse group of organizations tackling the issue of Veteran suicide.”

During Phase 2 of the challenge, 30 finalists will join a virtual accelerator program designed to help the finalists develop ambitious, but achievable roadmaps for prototyping, iteration, testing, and evaluation. Technology partners supporting the accelerator include Amazon and Microsoft.

In November 2022, finalists will present their solutions to key stakeholders, investors, and partners at Demo Day, a live pitch event. Phase 2 will award $11.5 million in prizes:

  • Two first-place winners will each receive $3 million,
  • Three second-place winners will each receive $1 million,
  • Five third-place winners will each receive $500,000.

Visit missiondaybreak.net for more information on the challenge. Subscribe to the Mission Daybreak newsletter to follow along with the finalists’ progress and receive updates on Demo Day. Reporters covering this issue can download VA’s Safe Messaging Best Practices fact sheet or visit ReportingOnSuicide.org for important guidance on how to communicate about suicide.

About NeuroFlow: NeuroFlow integrates behavioral health across the care continuum by assessing and triaging people to get them to the right level of care, providing high-tech and high-touch support for populations that would typically fall through the cracks in today’s healthcare system. Proven to drive better clinical and financial outcomes for leading health systems, payors, and the Department of Defense covering 15 million lives, NeuroFlow’s platform combines consumer engagement with enterprise-level care management software and clinical support services to support integrated behavioral health at scale. To learn more, visit http://www.neuroflow.com.

Share article on social media or email:

Labroots Announces Full Three-Day Agenda for its 10th Annual Cancer Research & Immuno-Oncology Week Event, Held on October 4-6, 2022


Cancer Research & Immuno-Oncology Week – October 4-6, 2022

Labroots, the leading scientific social networking website offering premier, interactive virtual events and webinars, is hosting its 10th annual Cancer Research and Immuno-Oncology Week conference on October 4-6, 2022. The three-day content-rich agenda continues to be the go-to-meeting sharing cutting-edge discoveries and novel advancements via invited lectures and thought-provoking discussions to improve the outcomes and treatments of patients with cancer.

Cancer Research & Immuno-Oncology Week offers a prestigious forum for some of the brightest minds in the field to collaborate and share knowledge in emerging topics including cancer research, novel targeted therapies in cancer, immuno-oncology, cell therapy, and cancer research networks, epidemiology and patient advocacy.

Over 30 educational and sponsored presentations will be presented by distinguished speakers covering all aspects of cancer care and immunotherapies with sessions on cancer health disparities – using genomics to influence clinical applications, single-cell methods for cancer discovery, using image analysis in cancer research and treatment, cancer systems biology, using spatial transcriptomics to dissect the tumor microenvironment, innovative approaches to target the oncoprotein K-Ras in cancer, neoantigen vaccines, next-generation checkpoint targets, overcoming the inhibitory tumor microenvironment, emerging cell therapies (beyond CAR T cells), and much more.

Naming just a few highlights, kicking off day one, Laura Yerly, PhD Candidate, Lausanne University Hospital CHUV, Laboratory of François Kuonen, MD, PD-MER, PhD will explore the invasive niche of basal cell carcinoma as revealed by integrated multi-omics with live Q&A during this presentation sponsored by NanoString Technologies.

Shortly thereafter, attendees will hear from keynote speaker Dr. Hugo Aerts, Director, Artificial Intelligence in Medicine (AIM) Program, Associate Professor, Harvard University, sharing a presentation titled, “Artificial Intelligence for Medical Imaging” with live Q&A. “While recent advances in AI have led to a profusion of studies that apply deep learning to problems in medicine, many of these algorithms fail to bridge the gap from a research study towards clinical application,” said Hugo Aerts, founding Director of the Artificial Intelligence in Medicine (AIM) program, Mass General Brigham and Harvard Medical School. “At this conference, I will discuss our approach to bridge this translational gap towards the clinic and will conclude with a discussion on the need for open-source deep learning frameworks that are transparent and reproducible.”

The second keynote presentation on day three also with live Q&A is presented by Chadi Nabhan, MD, MBA, FACP, Chairman, Precision Oncology Alliance & Adjunct Professor, University of South Carolina, Department of Clinical Pharmacy & Outcomes Sciences, Caris Life Sciences to explore precision oncology alliance: a vision to the future, you won’t want to miss! “The Caris Precision Oncology Alliance (POA0) is the premiere precision oncology consortium in the world focusing on advancing research to improve the outcomes of patients with cancer. Through the diverse contributions of our 71 members, we work towards investigating and understanding the latest scientific developments in genomics to advance the integration of molecular profiling into all aspects of cancer care through innovation and research. We look forward to sharing how this network was incepted, and how it contributes to the future of precision medicine at the upcoming Labroots conference,” commented Dr. Chadi Nabhan, Chairman, Prescision Oncology alliance & Adjunct Professor, University of South Carolina, Department of Clinical Pharmacy and Outcome Sciences.

“We’re thrilled to produce this must-attend event for 10 consecutive years, promising to expand your knowledge in the fast-developing interdisciplinary fields of cancer research and immuno-oncology,” said Greg Cruikshank, Chief Executive Officer of Labroots. “We’re proud to be on the forefront of driving emerging research on immunotherapies in combination with other anti-cancer targeted therapies via Labroots’ unique educational platform, with the aim to significantly improve the lives of patients and to fight cancer.”

Produced on Labroots’ signature platform, this online environment allows participants to connect across desktop and mobile devices delivering a seamless educational experience. The interactive environment features a lobby equipped with leaderboard and gamification, an auditorium, featuring live-streaming video webcasts offering live attendee chats during scheduled presentations, a poster hall with a poster competition, and attendees can explore data and engage in live chat conversations, an exhibit hall to interact with sponsors and view their recent contributions in the field, and lastly a networking lounge to connect and collaborate with colleagues. By participating in this event, you can earn 1 Continuing Education credit per watched presentation for a maximum of 35 credits.

To register for the event, click here. Use the hashtag #LRcancer to follow the conversation and connect with members of the global Cancer & Oncology Research community! Follow @Cancer_LR on Twitter and @CancerResearchandOncology.LR on Facebook to connect with our specialist Cancer & Oncology writers and stay up to date with the latest news in Cancer & Oncology Research. Now, you can also join our Cancer Research & Oncology networking group on LinkedIn!

About Labroots

Labroots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more. Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities. Founded in 2008, Labroots emphasizes digital innovation in scientific collaboration and learning. Offering more than articles and webcasts that go beyond the mundane and explore the latest discoveries in the world of science, Labroots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events. Now, Labroots offers more than ever with Chati, a flexible, highly scalable event platform that allows for the creation of unique, effective, and memorable virtual events.

Share article on social media or email:

Emerging Company Mode’s Must-Try Product, the Nano CBD Tincture, Has CBD Lovers Excited for the Future


Mode’s Nano CBD is bound to leave your body feeling relaxed and stress-free.

CBD tinctures have been popular for years now, but there are some innovative CBD manufacturers who are looking at different extraction methods to create more effective products. Mode has just launched their latest CBD product, the Nano CBD Tincture.

Nano CBD differs from a standard CBD product in the way it is manufactured. When CBD products are made, the CBD first must be extracted from the hemp plant. The extraction process is where nano CBD and CBD differ. When nano CBD is extracted, the CBD molecules are coated with small particles that help the CBD enter the bloodstream faster. This process also removes the terpenes in the hemp to produce a purer form of CBD. This form of extraction results in “nano-sized” molecules that are small enough for the user to absorb the entire dose of CBD and feel its effects within minutes.

This highly effective form of CBD has been able to help users who are suffering from issues such as anxiety, stress, chronic pains, sleep disorders, and depression. Users will experience these benefits all while maintaining mental agility and focus. If users are wondering about the THC content in nano CBD, it will be no different than a traditional CBD product. The extraction process leaves out the parts of the hemp plant that are responsible for a high and keeps the parts that provide mental and physical benefits.

While users will not experience any of the effects associated with THC in Mode’s Nano CBD Tincture, the physical feelings of relaxation upon consumption are easily noticeable. This heightened state of relaxation is what allows users to fall asleep faster, wake up refreshed, and experience decreased levels of stress and anxiety. CBD is especially effective for people with anxiety due to its ability to activate the serotonin receptors in the brain. Low serotonin is a major contributor of anxiety and depression.

In addition to improving sleep and symptoms of anxiety and depression, CBD is an effective tool to combat chronic pain. Mode’s Nano CBD Tincture is quickly becoming a favorite amongst people who suffer from chronic pain since it is also water-soluble. One reviewer points out that “Since MODE products are water soluble, my body absorbs the pain relieving properties in A LOT less time than it did with the previous oil based CBD I was on. And for those of us who suffer with chronic pain throughout our bodies, the faster we feel relief, the better.”

Being that Mode’s Nano CBD Tincture is water soluble, it can be mixed easily with water or food while simultaneously being absorbed quickly by the body. The water solubility, in conjunction with the unique nano extraction process, has CBD users everywhere excited about this innovative new product.

###

About Mode: Mode is a family-owned hemp-derived cannabis company that focuses on creating all-natural and lab-tested CBD products to help promote wellness of the body and mind. Mode has a strong focus on creating high-quality CBD products that are fast acting and highly effective. Their line includes topical as well as ingestible CBD products that are expertly crafted to ensure their maximum potency.

Share article on social media or email:

CMI Media Group Appoints Rebecca Mills as Executive Vice President


Headshot of Rebecca Mills, Executive Vice President, CMI Media Group

CMI Media Group Appoints Rebecca Mills as Executive Vice President

“Among the reasons I joined CMI Media Group is the company value of indispensability to clients. Their goals are our goals. I’m excited to be part of every touchpoint in our clients’ success,” said Mills.

CMI Media Group, a leading media strategy, planning, innovation and buying agency for the nation’s top healthcare companies and part of WPP, announced the executive appointment of Rebecca Mills as EVP, Group Client Director.

In this role as a business lead for one of the company’s key accounts, Mills will be partnering with the client to offer strategic, effective and efficient ways to move their business forward. She will also be ensuring that both the client and the team of media, data, customer experience and analytics experts working on their business receive the support and resources they need to thrive. She brings proven experience in strategic brand leadership across some of the nation’s best-known health and wellness brands. Mills will also be mentoring her team to ensure that every person touching the account brings proactive results.

Mills will be reporting to the company’s Chief Client Officer Melissa Barnhart, who said: “Our Group Client Directors are the CEOs of our largest clients. This is an enormous responsibility – one that Rebecca is well prepared for with her years of experience managing large cross-functional teams, spanning agency networks at an international scale.”

Mills is an accomplished media professional with nearly 20 years overseeing planning, investment, analytics, operations, communications strategy and custom content teams. Over the course of her career, she’s built a reputation for being a deeply entrenched client partner, innovative thinker, and inspirational team lead.

“Among the reasons I joined CMI Media Group is the company value of indispensability to clients. Their goals are our goals. I’m excited to be part of every touchpoint in our clients’ success,” said Mills. “My vision for this role is to ensure that our media plans are as innovative as the brands we serve. This isn’t innovation for innovations sake, this is innovation with a purpose. This is astute attentiveness. It is the rigor we apply when mining for insights that can change both our perspective and the path our plans take. It’s a strategy with a mission, because the brands we are privileged to work on can literally change and save lives. We owe this to our clients and even more so to the patients, their caregivers, and their trusted medical advisors.”

Mills will be overseeing client relationships, contracts, staffing, and most importantly, aiding the team in process, connection with other teams, and various actions that support successful client partnership.

Mills’ career has been centered on leading and representing major flagship brands including Johnson & Johnson’s Consumer Healthcare division, Estee Lauder, HSBC and Coca-Cola. Most recently, Mills worked within L’Oreal’s ACD division that homes in on medical and scientific skincare advancements with a focus on reaching dermatologists, primary care physicians, pediatricians, oncologists, and pharmacists. During the course of her career, she has been recognized for her work within the industry, receiving MIN’s “Sweet 16 Brand Advocates” as well as Johnson & Johnson’s “Rebel With A Cause” award focused on those who push forward in innovative ways in the healthcare space.

CMI Media Group is WPP’s leading healthcare media specialist. The company has brought many firsts to healthcare marketing as the premier healthcare-focused media buying and planning resource to the world’s game changers in pharma and life sciences.

Those looking to join the CMI Media Group team can visit the company’s career page for more information and a link to apply: https://cmimediagroup.com/careers/

About CMI Media Group

CMI Media Group, a WPP company (NYSE: WPP, http://www.wpp.com), is a full-service media agency focused solely on health, wellness, and pharmaceutical marketing. CMI Media Group’s core offerings include Audience Strategy, Planning, Development, and Insights; Data and Analytics; Buying and Investment; and Direct Response and Customer Experience. As the leading media resource for the world’s top healthcare companies, CMI Media Group brings together leading technology, data, and talent to deliver seamless capabilities for clients. CMI Media Group has been recognized as a leader in DE&I, talent retention and employee development as well as one of the industry’s best places to work. To apply for a position within our teams visit https://www.cmimediagroup.com/careers

Share article on social media or email:

Oxford Performance Materials to Provide 3D Printed Custom Orthopedic Implants and Suture Anchors for Ukraine War Victims


After a review of a range of articles and peer reviewed studies, we reached out to OPM, the world’s only provider of 3D printed PEKK polymer biomedical implants, with a demonstrated focus on complex patient-specific trauma cases.

Oxford Performance Materials, Inc. (OPM; https://oxfordpm.com/), an industry leader in advanced polymer science, 3D-printed orthopedic devices and coating technologies is pleased to announce an agreement to assist Orthopedic Help for Ukraine (OHFU) – a non-profit addressing the needs of orthopedic and surgery departments of Ukrainian hospitals – by manufacturing and delivering 3D printed custom implants along with suture anchors with instrument sets to front line hospitals treating people injured in the invasion of Ukraine by Russia. OHFU partner hospitals are receiving a massive influx of patients with critical bone defects from war-related trauma. Many of these injuries involve complex bone reconstruction, requiring rapid response patient-specific orthopedic solutions and materials with appropriate biocompatibility and purity. The nature of these traumatic injuries demand implants that are demonstrated to integrate with bone and have antibacterial properties to manage infection.

“A key part of OHFU’s mission is to identify new technologies and capabilities to rapidly treat a high rate of complex bone defect war injuries that result in a very high level of amputations,” said Janine Ignatenko, Executive Director of OHFU. “The current technologies available for the specific needs of our hospital partners are limited, and we have been investigating 3D printed implant technologies as a potential solution. After a review of a range of articles and peer reviewed studies, we reached out to OPM, the world’s only provider of 3D printed PEKK polymer biomedical implants, with a demonstrated focus on complex patient-specific trauma cases.”

OPM CEO Scott DeFelice commented, “OPM has been treating complex orthopedic trauma for over a decade, worldwide. Our technology utilizes a proprietary implantable PEKK polymer and 3D printing technology to manufacture patient specific implants, individually designed to fit perfectly into critical bone defects and then seamlessly integrate with the natural bone. Our PEKK material also has demonstrated antibacterial and antiviral properties. When OHFU reached out and showed us their enormous, complex case-load, our team was inspired, and we understood that we were uniquely positioned to impact their mission, improve case results and reduce amputations.”

Janine Ignatenko continued, “Surgeons in our hospital network also have a dire need for suture anchors for re-attaching soft tissue to bone. OPM’s suture anchor solution is perfect for our circumstances, providing bone ongrowth, inherent antibacterial characteristics, and low unit cost. In addition, OPM’s instrument sets are sterilizable and re-useable – an important benefit for our hospital partners. “Scott’s team has jumped in,” Ingatenko added. “OPM has shipped, pro-bono, an initial delivery of suture anchors and instruments and has already initiated the process toward a first patient specific implant case. OPM is a small company making a substantial commitment to be an ongoing supplier of pro-bono implants to OHFU partner surgeons. However, our caseload is tremendous, and our hope is to get individuals and organizations to provide support to our foundation so we can procure substantial volumes of products and services from OPM and other companies on a discounted basis. Finally, we recognize the unique nature of our ongoing clinical experience, and we will be providing clinically relevant data to support surgeons and patients in future global conflicts.”

To help support OHFU’s ongoing efforts to aid Ukrainian war victims, please donate directly at OHFU Donate Now.

About Orthopedic Help for Ukraine (OHFU)

Orthopedic Help for Ukraine (OHFU) was established as a non-profit humanitarian organization – a charity fund assisting Ukrainian hospitals to provide surgery, health care and recovery services to save the lives and address quality of life needs of the victims of the Russian invasion. Established in May 2022 by volunteers and doctors, OHFU is a nonprofit with no political or religious affiliation working to ensure rapid and flexible funding and supply of medical equipment, disposables and medicines to Ukrainian hospitals that are working tirelessly to provide surgical procedures and treatment utilizing high-quality implants and prostheses. OHFU also helps relieve pressure on the European public health system by aiding the funding and provision of medications, diagnostic means, disposable and consumable materials, spare parts and/or necessary medical equipment and supplies to the orthopedic and surgical departments of Ukrainian hospitals that provide healthcare and emergency services to patients in critical condition. ‍Inquiries to OHFU:

Janine Ignatekno, Executive Director

Orthopedic Help for Ukraine (OHFU)

Orthopedichelpukraine@gmail.com

Link for direct donations: OHFU Donate Now About Oxford Performance Materials, Inc.

Oxford Performance Materials, Inc. (OPM) was founded in 2000 to develop and commercialize the world’s highest performing thermoplastic, PEKK (poly-ether-ketone-ketone). OPM’s Materials business has developed a range of proprietary, patented technologies for the synthesis and modification of a range of PAEK polymers that are sold under its OXPEKK® brand, including coating technologies for a range of industrial and biomedical applications. OPM is a pioneer in 3D printing. OPM’s OsteoFab® technology is in commercial production in numerous orthopedic implant applications, including cranial, facial, spinal, and sports medicine devices, and OPM’s OXFAB® production parts are designed for highly demanding industrial applications. Business or Media Inquiries to Oxford Performance Materials:

Bernard Plishtin

Oxford Performance Materials, Inc.

917.494.3649

bplishtin@oxfordpm.com

Share article on social media or email:

2022 Evolution of Psychotherapy Orlando conference features masters, breakout thinkers in refreshed educational program


Evolution of Psychotherapy logo

The Evolution of Psychotherapy meeting welcomes back the masters of psychotherapy and new presenters to discuss emerging, future-focused topics that expand on the fundamentals of effective care.

“This year at Evolution of Psychotherapy Orlando, we are embracing what an evolution truly means: to change, develop, and grow,” said Jeffrey Zeig, PhD, conference chairman and director and founder of The Milton H. Erickson Foundation.

This year’s Evolution of Psychotherapy meeting welcomes back the masters of psychotherapy and welcomes new presenters to discuss emerging, future-focused topics that expand on the fundamentals of effective care.

The four-day integrated forum is slated for December 14-17 in Orlando. Dubbed the “Woodstock of Psychotherapy” by TIME magazine in 1985, the meeting allows established experts, forward thinkers, and on-the-ground professionals to connect, engage, support, and reinvigorate their practice in the field of psychotherapy.

“This year at Evolution of Psychotherapy Orlando, we are embracing what an evolution truly means: to change, develop, and grow,” said Jeffrey Zeig, PhD, conference chairman and director and founder of The Milton H. Erickson Foundation. “It is a practice-changing event crafted by experts and inspired by our attendees, where foundational principles will inspire future practices.”

The educational program features a returning core group of more than 20 world-renowned faculty, providing an experience familiar to past attendees. Keynote speakers include:


  • Dan Siegel, MD, co-founder and executive director of the Mindsight Institute
  • Helen Fisher, PhD, internationally renowned neuroscientist, biological anthropologist, and chief scientific advisor on Match.com
  • Otto F. Kernberg, MD, FAPA, professor of psychiatry, Weill Cornell Medical College
  • Stephen Porges, PhD, distinguished university scientist, Indiana University and author of The Polyvagal Theory
  • Diane Ackerman, MA, MFA, PhD, bestselling author of 26 books of prose and poetry

Voices new to the Evolution stage are the focus of reTHINK sessions, with short and impactful presentations delivered by practitioners covering future-focused topics including psychedelics and technology-augmented psychotherapy. Their groundbreaking ideas are designed to spark deep conversations that will examine current challenges in mental health.

The reTHINK sessions are moderated by Saundra Jain, MA, PsyD, LPC, adjunct clinical affiliate, University of Texas at Austin School of Nursing. Speakers include:

  • Gowri Aragam, MD, clinical instructor in psychiatry, Harvard Medical School, Massachusetts General Hospital; co-founder, Stanford Brainstorm Lab for Mental Health Innovation at Massachusetts General Hospital
  • Heather Berlin, PhD, associate clinical professor of psychiatry and neuroscience, Icahn School of Medicine at Mount Sinai
  • Robin Carhart-Harris, PhD, Ralph Metzner Distinguished Professor of Neurology and Psychiatry, and director of Psychedelics Division, Neuroscape, University of California San Francisco
  • Mary-Frances O’Connor, PhD, associate professor, University of Arizona
  • Sheryl Gonzalez Ziegler, PhD, founder, The Child and Family Therapy Center at Lowry

Participants can earn more than 60 continuing education credits in specific areas required for re-licensure, including domestic violence, ethics, and telehealth. The conference is open to professionals in mental health and health-related fields, including marriage and family therapists, clinical and counseling psychologists, psychiatric social workers, pastoral counselors, psychotherapists, psychiatrists, physicians, nurse practitioners, counselors, and graduate students.

Included in the conference registration are two complimentary pre-conferences on ethical decision making and adolescent and young adult treatment strategies.

For more information or to register, visit evolutionofpsychotherapy.com.

ABOUT HMP GLOBAL

HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

Share article on social media or email:

Nellson To Consolidate Nutritional Powder Manufacturing Facilities


Nellson logo

The significant operational and productivity improvements in Anaheim created the opportunity for consolidation—while ensuring ample growth capacity for the future—which led us to conclude that closing our Salt Lake City facility is in the best interests of both Nellson and our clients.

Nellson Nutraceutical LLC (“Nellson”), a leading North American manufacturer of branded and private label nutritional bars and functional powder solutions, has announced a restructuring plan, which will cease manufacturing operations in its Salt Lake City, Utah facility by the end of December and consolidate its nutritional powder volume, manufacturing equipment and assets to its Anaheim, California facility.

“After extensive evaluation, Nellson has made the strategic decision to consolidate facilities and cease operations in Salt Lake City,” said Jean Filion, Chief Executive Officer of Nellson. “Over the past few years, we have invested in expanding the capacity and capabilities of our powder facilities. The significant operational and productivity improvements in Anaheim created the opportunity for consolidation—while ensuring ample growth capacity for the future—which led us to conclude that closing our Salt Lake City facility is in the best interests of both Nellson and our clients. This decision was not easy, but we believe it will substantially enhance our ability to serve our brand partners effectively and facilitate making further investments in our market-leading capabilities.”

Bart Child, Nellson’s Chief Commercial Officer, said, “Anaheim has all the manufacturing assets and capacity needed to make the volume and product formats currently produced in Salt Lake City, as many of those products are already produced in both plants. While we expect to transfer some of Salt Lake City’s assets to further enhance Anaheim’s capacity and capabilities, none of those assets are required to effectuate the volume transfers.”

Added Filion, “Over the last five years, Nellson has invested heavily in assembling best-in-class manufacturing assets in both its bar and powder facilities. This decision continues that trend and furthers our ability to provide our brand partners with market-leading product innovation and service. We thank all of our Salt Lake employees for their contributions, service and dedication to the company and pledge our continued support to affected employees during this time.”

###

About Nellson

Nellson, the leading full-service nutritional bar and powder provider in North America, is based in Anaheim, California with production locations in California, Utah, and Quebec. Founded in 1962, Nellson has 60 years of diversified expertise in nutrition platforms for bars and powders, serving the sports performance, health and wellness, weight management, and medical nutrition market segments. Nellson offers formulation expertise, quality assurance, regulatory support, flexible production, and sales and marketing support.

Share article on social media or email: